RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
Start of invitations for the seasonal flu vaccination The invitation for the seasonal flu vaccination will land on your doormat this autumn. The flu vaccination protects people who are more likely to become ill or seriously ill from flu because of their age or medical condition.
Safety of materials and products already starts at the design phase The Ministry of Infrastructure and Water Management aims to ensure that all new materials and technological developments are safe in 2050.
COVID-19 consequences impact vulnerable groups more in the long term The effects of the corona crisis have a greater impact on vulnerable groups in society, such as lower-educated adults, young people, the elderly and people with underlying health problems.
First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
Health effects due to titanium nanoparticles in food and toothpaste cannot be excluded Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.